Effects of single-dose praziquantel on morbidity and mortality resulting from intestinal schistosomiasis

Simple item page
dc.creatorKheir, M.M.
dc.date2014-06-17T10:53:34Z
dc.date2014-06-17T10:53:34Z
dc.date2000-12-31
dc.date.accessioned2026-08-03T07:29:10Z
dc.description926-931
dc.descriptionThe long-term effect of single-dose praziquantel on morbidity and mortality from Schistosoma mansoni was investigated in surveys in 1987 and 1994 in central Sudan. Prevalence of infection dropped from 53% to 34%, and intensity of infection [400 eggs/g of faeces] from 31% to 18%. There was a reduction in hepatomegaly and hepatosplenomegaly, although splenomegaly alone was unchanged. Prevalence of periportal fibrosis decreased from 14% to 10%. Endoscopic investigation of patients with fibrosis showed a reduction in oesophageal varices from 47% to 30%. Mortality due to bleeding varices was high [community-wide, up to 11/100 infected patients with bleeding]. Thus praziquantel mass treatment can be spaced to a much longer period, reducing the expense of treatment, delivery and distribution
dc.formatapplication/pdf
dc.identifier1020-3397
dc.identifierhttp://applications.emro.who.int/emhj/0605_6/EMHJ_2000_6_5-6_926_931.pdf
dc.identifierhttps://iris.who.int/handle/10665/118947
dc.identifier.urihttps://repo.dare.co.zw/handle/123456789/216296
dc.languageEnglish
dc.languageen
dc.relationEMHJ - Eastern Mediterranean Health Journal, 6 (5-6), 926-931, 2000
dc.subjectPraziquantel
dc.subjectEsophageal and Gastric Varices
dc.subjectSchistosomiasis mansoni
dc.subjectLiver Cirrhosis
dc.subjectSchistosomiasis mansoni
dc.subjectPrevalence
dc.subjectSchistosomiasis mansoni
dc.titleEffects of single-dose praziquantel on morbidity and mortality resulting from intestinal schistosomiasis

Files

Collections

WHO IRIS